7-Hydroxy Cannabidiol Lowers Triglycerides in NAFLD
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for non-alcoholic fatty liver disease (NAFLD) lack specific medications to effectively lower triglyceride levels, which are associated with obesity, type II diabetes, and increased risk of cardiovascular diseases, and existing medications have limitations in achieving this goal.
Innovation Solution
A pharmaceutical composition comprising 7-hydroxy-cannabidiol (7-OH-CBD) is used to treat NAFLD, formulated in a pharmaceutically acceptable carrier, potentially in combination with other medicaments, for administration via various routes, aiming to lower triglyceride levels by being more potent than its parent compound CBD.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing medications are used to treat NAFLD, then some beneficial effects on the liver are achieved, but they fail to effectively lower triglyceride levels
Solution Approach 1:
The patent changes the chemical parameter by using a specific metabolite (7-OH-CBD) rather than the parent compound (CBD), resulting in enhanced potency for lowering triglyceride levels in NAFLD patients
Solution Approach 2:
The patent extracts and isolates the specific active metabolite 7-OH-CBD from the metabolism pathway of CBD, focusing therapeutic action on this specific compound that demonstrates superior triglyceride-lowering effects compared to other medications
2Reliability
If lifestyle changes such as diet and exercise are implemented, then triglyceride levels can be lowered, but adherence and effectiveness are difficult to achieve
Solution Approach 1:
The patent introduces 7-OH-CBD as a pharmacological intermediary that mediates triglyceride reduction, providing a chemical solution that complements or替代s the difficult lifestyle modifications required for achieving the same therapeutic effect
3Reliability
If higher doses of CBD are used to achieve triglyceride lowering, then potency increases, but potential toxicity and side effects increase
Solution Approach 1:
The patent changes the chemical structure parameter by using the metabolite 7-OH-CBD instead of CBD, achieving higher potency at lower doses and thereby reducing the risk of toxicity and side effects associated with higher doses of parent compounds
Data Source
AI summary
The liver plays a key role in regulating total body energy homeostasis and its ability to do so is greatly affected by the occurrence of pathological conditions such as hepatosteatosis or non-alcoholic fatty liver disease (NAFLD), which contributes to hepatic insulin resistance and potentially end-stage liver disease-related mortality. Triglyceride accumulation in hepatocytes of steatotic livers results from the incorporation of plasma free fatty acids as well as de novo fat synthesis. The present invention relates to the use of 7-hydroxy-cannabidiol (7-OH-CBD) in the treatment of non-alcoholic fatty liver disease (NAFLD). Treatment of NAFLD involves lowering the triglyceride levels in a patient's blood stream.